Vanguard Group
CARM

Vanguard Group’s Carisma Therapeutics CARM Stock Holding History

Vanguard Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-350,324
Closed -$96K – 4344
2025
Q3 		$96K Hold
350,324
– – ﹤0.01% 4231
2025
Q2 		$137K Sell
350,324
-1,045,284
-75% -$280K ﹤0.01% 4118
2025
Q1 		$433K Sell
1,395,608
-23,240
-2% -$10.3K ﹤0.01% 3919
2024
Q4 		$594K Sell
1,418,848
-29,399
-2% -$24.2K ﹤0.01% 3893
2024
Q3 		$1.42M Hold
1,448,247
– – ﹤0.01% 3665
2024
Q2 		$2.2M Sell
1,448,247
-131,714
-8% -$196K ﹤0.01% 3527
2024
Q1 		$3.59M Buy
1,579,961
+11,200
+0.7% +$26.9K ﹤0.01% 3418
2023
Q4 		$4.6M Buy
1,568,761
+8,435
+0.5% +$25.1K ﹤0.01% 3324
2023
Q3 		$6.6M Buy
1,560,326
+50,864
+3% +$322K ﹤0.01% 3123
2023
Q2 		$13.2M Buy
1,509,462
+943,743
+167% +$5.14M ﹤0.01% 2792
2023
Q1 		$1.75M Buy
565,719
+23,004
+4% +$219K ﹤0.01% 3726
2022
Q4 		$6.62M Buy
542,715
+212
+0% +$2.23K ﹤0.01% 3159
2022
Q3 		$4.61M Buy
542,503
+5,384
+1% +$73.3K ﹤0.01% 3373
2022
Q2 		$8.71M Sell
537,119
-97,620
-15% -$1.12M ﹤0.01% 3069
2022
Q1 		$7.65M Buy
634,739
+16,401
+3% +$229K ﹤0.01% 3292
2021
Q4 		$10.1M Buy
618,338
+108,161
+21% +$2.18M ﹤0.01% 3199
2021
Q3 		$8.09M Buy
510,177
+84,978
+20% +$4.08M ﹤0.01% 3371
2021
Q2 		$39.3M Buy
425,199
+65,421
+18% +$4.17M ﹤0.01% 2494
2021
Q1 		$18.7M Buy
359,778
+65,097
+22% +$3.07M ﹤0.01% 2821
2020
Q4 		$7.96M Buy
294,681
+59,674
+25% +$1.51M ﹤0.01% 3110
2020
Q3 		$6.58M Buy
235,007
+34,946
+17% +$699K ﹤0.01% 3011
2020
Q2 		$2.88M Sell
200,061
-30
-0% -$405 ﹤0.01% 3322
2020
Q1 		$2.24M Hold
200,091
– – ﹤0.01% 3270
2019
Q4 		$4.16M Buy
200,091
+8,327
+4% +$191K ﹤0.01% 3225
2019
Q3 		$4.49M Buy
191,764
+14,036
+8% +$328K ﹤0.01% 3175
2019
Q2 		$5.33M Buy
177,728
+1,111
+0.6% +$33.3K ﹤0.01% 3142
2019
Q1 		$3.64M Buy
176,617
+41,692
+31% +$720K ﹤0.01% 3256
2018
Q4 		$3.83M Buy
134,925
+8,980
+7% +$286K ﹤0.01% 3173
2018
Q3 		$5.42M Buy
125,945
+22,748
+22% +$886K ﹤0.01% 3204
2018
Q2 		$4.03M Buy
103,197
+81,341
+372% +$3.58M ﹤0.01% 3281
2018
Q1 		$459K Buy
21,856
+5,512
+34% +$106K ﹤0.01% 3802
2017
Q4 		$265K Buy
16,344
+7,129
+77% +$133K ﹤0.01% 3879
2017
Q3 		$291K Sell
9,215
-1,108
-11% -$31K ﹤0.01% 3846
2017
Q2 		$324K Buy
10,323
+1,530
+17% +$51K ﹤0.01% 3804
2017
Q1 		$386K Buy
8,793
+2,735
+45% +$114K ﹤0.01% 3798
2016
Q4 		$231K Buy
6,058
+375
+7% +$16.5K ﹤0.01% 3866
2016
Q3 		$319K Buy
5,683
+1,800
+46% +$134K ﹤0.01% 3829
2016
Q2 		$130K Hold
3,883
– – ﹤0.01% 3997
2016
Q1 		$25K Sell
3,883
-6,327
-62% -$87.5K ﹤0.01% 4114
2015
Q4 		$614K Buy
10,210
+621
+6% +$35.3K ﹤0.01% 3776
2015
Q3 		$462K Buy
9,589
+3,952
+70% +$244K ﹤0.01% 3870
2015
Q2 		$318K Buy
5,637
+547
+11% +$77.2K ﹤0.01% 3970
2015
Q1 		$908K Buy
5,090
+337
+7% +$73.6K ﹤0.01% 3658
2014
Q4 		$1.13M Buy
4,753
+29
+0.6% +$6.5K ﹤0.01% 3493
2014
Q3 		$1.05M Buy
4,724
+401
+9% +$95.3K ﹤0.01% 3490
2014
Q2 		$1.14M Sell
4,323
-21
-0.5% -$5.2K ﹤0.01% 3455
2014
Q1 		$1.41M Buy
+4,344
New +$1.3M ﹤0.01% 3346

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Vanguard Group's CARM Position: Q4 2025 in Review

Vanguard Group sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 350,324 shares — an estimated $96K sold.

Vanguard Group first reported a position in CARM in Q1 2014 and held it in 47 quarters. The position peaked at $39.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Vanguard Group reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Vanguard Group sold 350,324 Carisma Therapeutics shares in Q4 2025, an estimated $96K.
  • Vanguard Group first reported a position in Carisma Therapeutics in Q1 2014 and held it in 47 quarters.
  • Vanguard Group's Carisma Therapeutics position peaked at $39.3M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.